Jazz Pharmaceuticals plc — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On September 23, 2026, Jazz Pharmaceuticals executed Amendment No. 4 to its credit agreement, refinancing Tranche B-2 Dollar Term Loans into Tranche B-3 Dollar Term Loans. Bank of America committed to provide $273.3M in new Tranche B-3 financing; consenting lenders either converted their B-2 holdings or had them repaid and purchased B-3 loans. Total B-3 commitment equals $1.895B. Margin on B-3 loans is 1.75% for SOFR loans and 0.75% for ABR loans, identical to prior pricing. The refinancing maintains existing loan terms while establishing a new tranche class.
Why this rating
Routine debt refinancing with no principal increase or material terms change. Event is administrative—converts existing loans to new class. Immaterial relative to $6.3B market cap (~3% of company size).
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.